LLG783X
Total Payments
$64,686
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $64,396 | 1 | 0 |
| 2017 | $290.58 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $64,686 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PATIENT AND INVESTIGATOR BLINDED RANDOMIZED PLACEBO CONTROLLED STUDY OF LLG783 IN PATIENTS WITH PERIPHERAL ARTERY DISEASE PAD AND INTERMITTENT CLAUDICATION | Novartis Pharmaceuticals Corporation | $64,686 | 0 |
Top Doctors Receiving Payments for LLG783X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $64,686 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $64,686
- Total Doctors 0
- Transactions 2
About LLG783X
LLG783X is a drug associated with $64,686 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $64,396 was paid across 1 transactions to 0 doctors.
The most common payment nature for LLG783X is "Unspecified" ($64,686, 100.0% of total).
LLG783X is associated with 1 research study, including "A PATIENT AND INVESTIGATOR BLINDED RANDOMIZED PLACEBO CONTROLLED STUDY OF LLG783 IN PATIENTS WITH PERIPHERAL ARTERY DISEASE PAD AND INTERMITTENT CLAUDICATION" ($64,686).